(secondQuint)Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma.

 Although anti-angiogenesis therapy for glioblastoma(GBM) are showing promise, GBMs often develop resistance to treatment within months or weeks after salvage therapy.

 There are still no effective markers to predict the response rate to bevacizumab.

 So the investigators initiate a single-arm Phase II study to evaluate the efficacy and tolerability of bevacizumab and nimustine regimen and to explore the predictive markers in patients with recurrent high-grade glioma.

.

 Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma@highlight

The purpose of this study is to determine whether bevacizumab and nimustine are effective in the treatment of recurrent high grade glioma and to explore whether there is any subgroup being sensitive to this therapeutic protocol.

